Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome

2020-04-01 04:26:51 | BioPortfolio


COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution to the lack of ICU beds and increasing deaths day after day.

A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically ill patients. We're routinely using MP for severe pneumonia-ARDS with acute respiratory failure with very good results.

The main objective of this multi-centre observational trial is to evaluate the efficacy of low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute respiratory syndrome.


Comparison of two groups of patients SARS-CoV-2 positive with severe acute respiratory syndrome:

1. Consecutively treated with low prolonged doses of methylprednisolone

2. Historical patients never treated with corticosteroids

The two group will be matched (1:1) according to the following criteria:

1. sex

2. age <10 years difference

3. CRP level at admission (difference <20%)

4. SOFA score (difference <20%)

5. P/F difference <20%

Anti-viral agents, chloroquine, respiratory support (any), and antibiotics (any) will be permitted to each study group.

Corticosteroids use, other than methylprednisolone for MP-treated group is a reason of drop-out.

1. Methylprednisolone treated-group will receive at study entry Methylprednisolone 80mg iv bolus followed by Methylprednisolone 80mg in 240cc 0.9% saline iv infusion at 10cc/h for at least 8 days or more until PCR<20mg/L and/or P/F>350. Then methylprednisolone 16mg BID os slowly tapering until PCR normal range +/- normal range and P/F>400.

Group 1 will be treated also with usual respiratory support (oxygen, O2 high-flow nasal cannula, CPAP, noninvasive ventilation, invasive mechanical ventilation, ECMO).

2. Control group will be selected and matched among historical patients with the same disease and treatment, but without any administration of methylprednisolone and other corticosteroids.

Matching criteria will be the following (all of them):

1. same sex

2. age +/- 10 years

3. C-reactive protein within 20% value difference

4. P/F within 20% value difference

5. SOFA score within 20% value difference

Study Design


Severe Acute Respiratory Syndrome (SARS) Pneumonia


Methylprednisolone, standard care


Marco Confalonieri




University of Trieste

Results (where available)

View Results


Published on BioPortfolio: 2020-04-01T04:26:51-0400

Clinical Trials [7035 Associated Clinical Trials listed on BioPortfolio]

Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life

In December 2019 a new kind of virus was identified in China as the responsible of severe acute respiratory syndrome (SARS) and interstitial pneumonia. Severe acute respiratory syndrome co...

Investigating Severe Acute Respiratory Syndrome (SARS)

Severe Acute Respiratory Syndrome (SARS) is a newly recognized illness that can be fatal. The purpose of this study is to better understand SARS by collecting samples of blood and other b...

Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome

Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel coronavirus (SARS-CoV). The major clinical features of SARS include fever, dyspnea, lymphopenia...

Nitric Oxide Gas Inhalation for SARS-CoV-2

Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to refract...

The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes

Severe acute respiratory syndrome (SARS) is a new threat to public health since November, 2002. The SARS is highly contagious and is believed to be transmitted by person-to-person through ...

PubMed Articles [29529 Associated PubMed Articles listed on BioPortfolio]

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infec...

Liver injury during highly pathogenic human coronavirus infections.

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the pathogen of 2019 novel coronavirus disease (COVID-19), has posed a serious threat to global public health. The WHO has declared th...

Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?

Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China.

We report co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus in a patient with pneumonia in China. The case highlights possible co-detection of known ...

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.

Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern glo...

Medical and Biotech [MESH] Definitions

A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus.

A coronavirus first reported in the summer of 2012 in a pneumonia patient in SAUDI ARABIA. It is related to SARS VIRUS. MERS-CoV has an estimated incubation period of 12 days and symptoms include renal failure and severe acute pneumonia with often fatal outcome.

A viral disorder characterized by high FEVER, dry COUGH, shortness of breath (DYSPNEA) or breathing difficulties, and atypical PNEUMONIA. A virus in the genus CORONAVIRUS is the suspected agent.

A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.

A clinical syndrome with acute abdominal pain that is severe, localized, and rapid onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases.

More From BioPortfolio on "Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome"

Quick Search

Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Searches Linking to this Trial